Reflection on the current status of endometrial cancer in New Zealand.
endometrial cancer
genomics
obesity
opinion
Journal
The Australian & New Zealand journal of obstetrics & gynaecology
ISSN: 1479-828X
Titre abrégé: Aust N Z J Obstet Gynaecol
Pays: Australia
ID NLM: 0001027
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
11
06
2019
accepted:
09
08
2019
pubmed:
13
9
2019
medline:
5
9
2020
entrez:
13
9
2019
Statut:
ppublish
Résumé
Incidence of endometrial cancer is increasing rapidly in the developed world and is the most common gynaecological cancer in Australia and New Zealand. In line with obesity rates, the landscape and average age of women diagnosed with endometrial cancer are changing. There is still unmet need in early diagnosis, directed treatment, management of comorbidities and prevention strategies. This opinion piece aims to reflect on the current status of endometrial cancer in New Zealand in parallel to Australia, drawing out areas for future research and discussion.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
874-876Informations de copyright
© 2019 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
Références
Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol 2016; 34: 4225-4230.
Beavis AL, Cheema S, Holschneider CH et al. Almost half of women with endometrial cancer or hyperplasia do not know that obesity affects their cancer risk. Gynecol Oncol Rep 2015; 13: 71-75.
Firestone RT, Ellison-Loschmann L, Shelling AN et al. Ethnic differences in disease presentation of uterine cancer in New Zealand women. J Fam Plann Reprod Health Care 2012; 38: 239-245.
Lawton B, Filoche SK, Rose SB et al. Uterine cancer: exploring access to services in the public health system. Aust N Z J Obstet Gynaecol 2014; 54: 457-461.
Lee CH, Sibley CG. Demographic and psychological correlates of satisfaction with healthcare access in New Zealand. N Z Med J 2017; 130: 11-24.
Hakkaart C, Ellison-Loschmann L, Day R et al. Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori. Fam Cancer 2019; 18: 83-90.
Shaw V, Vandal AC, Coomarasamy C, Ekeroma AJ. The effectiveness of the levonorgestrel intrauterine system in obese women with heavy menstrual bleeding. Aust N Z J Obstet Gynaecol 2016; 56: 619-623.
Pal N, Broaddus RR, Urbauer DL et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol 2018; 131: 109-116.
Murray CM, Roke C. Who can afford a Mirena® for contraception? J Prim Health Care 2018; 10: 201-206.
Broughton C. Pharmac failure to fund effective contraceptive ‘embarrassing’ Stuff.co.nz, 2019.
Group NZGC. NZGCG Follow up Recommendations for Endometrial and Cervical cancer, 2015. Available From https://www.health.govt.nz/system/files/documents/publications/2015_nzgcg_follow_up_recommendations_0.pdf.
Scott OW, Tin Tin S, Bigby SM, Elwood JM. Rapid increase in endometrial cancer incidence and ethnic differences in New Zealand. Cancer Causes Control 2019; 30: 121-127.
Rowlands IJ, Lee C, Beesley VL et al. Women's perceptions of their lifestyle and quality of life several years after a diagnosis of endometrial cancer. Cancer Nurs 2015; 38: E21-E28.
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17.
Levine DA, The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67.
Stelloo E, Nout RA, Osse EM et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res 2016; 22: 4215-4224.
Yen TT, Wang TL, Fader AN et al. Molecular classification and emerging targeted therapy in endometrial cancer. Int J Gynecol Pathol 2019. [Epub ahead of print]. https://doi.org/10.1097/PGP.0000000000000585
Church DN, Stelloo E, Nout RA et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst 2015; 107: 402.
van Gool IC, Eggink FA, Freeman-Mills L et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res 2015; 21: 3347-3355.
Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP) National Human Genome Research Institute, 2018.